Evidence map›Paper›PMID 32933107›Full record

ArticleInternational journal of molecular sciences2020

Integrated Analysis to Study the Relationship between Tumor-Associated Selenoproteins: Focus on Prostate Cancer.

Francesca Capone, Andrea Polo, Angela Sorice, Alfredo Budillon, Susan Costantini

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05817227 (Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer.), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05817227 recruitingnot on this mapstarted 2022, after this paper: background citation

Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer.

TypeobservationalSponsorNational Cancer Institute, NaplesRan2022 to 2027Enrolled300ConditionsBreast Cancer
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Selenoprotein K at the intersection of cellular pathways.Archives of biochemistry and biophysics · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Francesca CaponeUnità di Farmacologia Sperimentale-Laboratori di Mercogliano, Istituto Nazionale Tumori "Fondazione G. Pascale"-IRCCS, 80131 Napoli, Italy.
Andrea PoloUnità di Farmacologia Sperimentale-Laboratori di Mercogliano, Istituto Nazionale Tumori "Fondazione G. Pascale"-IRCCS, 80131 Napoli, Italy.
Angela SoriceUnità di Farmacologia Sperimentale-Laboratori di Mercogliano, Istituto Nazionale Tumori "Fondazione G. Pascale"-IRCCS, 80131 Napoli, Italy.
Alfredo BudillonUnità di Farmacologia Sperimentale-Laboratori di Mercogliano, Istituto Nazionale Tumori "Fondazione G. Pascale"-IRCCS, 80131 Napoli, Italy.ORCID 0000-0001-6631-3550
Susan CostantiniUnità di Farmacologia Sperimentale-Laboratori di Mercogliano, Istituto Nazionale Tumori "Fondazione G. Pascale"-IRCCS, 80131 Napoli, Italy.
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Selenoproteins are proteins that contain selenium within selenocysteine residues. To date, twenty-five mammalian selenoproteins have been identified; however, the functions of nearly half of these selenoproteins are unknown. Although alterations in selenoprotein expression and function have been suggested to play a role in cancer development and progression, few detailed studies have been carried out in this field. Network analyses and data mining of publicly available datasets on gene expression levels in different cancers, and the correlations with patient outcome, represent important tools to study the correlation between selenoproteins and other proteins present in the human interactome, and to determine whether altered selenoprotein expression is cancer type-specific, and/or correlated with cancer patient prognosis. Therefore, in the present study, we used bioinformatics approaches to (i) build up the network of interactions between twenty-five selenoproteins and identify the most inter-correlated proteins/genes, which are named HUB nodes; and (ii) analyze the correlation between selenoprotein gene expression and patient outcome in ten solid tumors. Then, considering the need to confirm by experimental approaches the correlations suggested by the bioinformatics analyses, we decided to evaluate the gene expression levels of the twenty-five selenoproteins and six HUB nodes in androgen receptor-positive (22RV1 and LNCaP) and androgen receptor-negative (DU145 and PC3) cell lines, compared to human nontransformed, and differentiated, prostate epithelial cells (EPN) by RT-qPCR analysis. This analysis confirmed that the combined evaluation of some selenoproteins and HUB nodes could have prognostic value and may improve patient outcome predictions.

Indexed as

AnimalsCell LineCell Line, TumorEpithelial CellsGene ExpressionHumansMaleMiceMice, NudePC-3 CellsPrognosisProstateProstatic NeoplasmsReceptors, AndrogenSelenoproteinsReceptors, AndrogenSelenoproteinscancerHUB nodesprostate cancerselenoproteins

Identifiers

PMID32933107
PMCPMC7555134
OpenAlexW3086776183

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.